Angiogenic factors in preeclampsia: potential for diagnosis and treatment.
Angiogenic factors in preeclampsia: potential for diagnosis and treatment.
复制标题
DOI：
10.1097/mnh.0b013e328365ad98
复制
发表时间：
2013-11
影响因子：
3.2
通讯作者：
Rana S
中科院分区：
文献类型：
--
作者：
Goel A;Rana S
该综述总结了循环血管生成因子在诊断、管理和治疗先兆子痫中关键作用的新观察结果。先兆子痫中循环血管生成因子（可溶性 fms 样酪氨酸激酶 1 和胎盘生长因子）的改变与子痫前期的诊断和不良后果相关，特别是当疾病过早出现时（<34 周）。这些血管生成生物标志物的测量进一步有助于将先兆子痫及其并发症与具有相似临床特征的其他疾病区分开来。可溶性 fms 样酪氨酸激酶 1/胎盘生长因子的比率大于 85 似乎是诊断和预后的理想临界点。还有证据表明调节这些因子具有治疗作用，表明血管生成因子在治疗和预防先兆子痫中的未来作用。循环血管生成生物标志物有助于先兆子痫的诊断和预后分析，并可能有助于更好地管理这些患者。
The review summarizes new observations of key roles for circulating angiogenic factors in diagnosing, managing, and treating preeclampsia. Alterations in circulating angiogenic factors (soluble fms-like tyrosine kinase-1 and placental growth factor) in preeclampsia correlate with the diagnosis and adverse outcomes, particularly when the disease presents prematurely (<34 weeks). Measurement of these angiogenic biomarkers further helps differentiate preeclampsia and its complications from other disorders that present with similar clinical profiles. A ratio of soluble fms-like tyrosine kinase-1/placental growth factor greater than 85 appears ideal as the cut-off for both diagnosis and prognosis. There is also evidence that modulating these factors has therapeutic effects, suggesting a future role for angiogenic factors in treatment and prevention of preeclampsia. Circulating angiogenic biomarkers help in diagnostic and prognostic profiling of preeclampsia and may facilitate better management of these patients.